Section Head, Advanced Heart Failure and Transplantation, Henry Ford Hospital Associate Professor, Internal Medicine, Wayne State University School of Medicine
Cardiology
Dr. David E. Lanfear, MD
|
|
Give Review
David Lanfear works in the field of Cardiology. He researched medicine at University of Michigan Medical School. He received awards:"Fellow (FAHA)", "CMS Meaningful Use Stage 1 Certification" and "Fellow (FACC)". David Lanfear is a published physician as well. He has 58 publications published. The latest was: Genetic Factors Influencing B-type Natriuretic Peptide-Mediated Production of Cyclic Guanosine Monophosphate and Blood Pressure Effects in Heart Failure Patients. David Lanfear accepts Medicare payments and is registered with Medicare.gov.
Publications
- Genetic Factors Influencing B-type Natriuretic Peptide-Mediated Production of Cyclic Guanosine Monophosphate and Blood Pressure Effects in Heart Failure Patients.
- Association of antidiabetic medications targeting the glucagon-like Peptide 1 pathway and heart failure events in patients with diabetes.
- Cardiac Rehabilitation Improves Functional Capacity and Patient-Reported Health Status in Patients With Continuous-Flow Left Ventricular Assist Devices: The Rehab-VAD ...
- Relationship of tricuspid repair at the time of left ventricular assist device implantation and survival.
- Assessing the Potential of E-mail for Communicating Drug Therapy Recommendations to Physicians in Patients With Heart Failure and Ventricular-Assist Devices.
- Type of β-blocker use among patients with versus without diabetes after myocardial infarction.
- Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction.
- Differing Effects of Metformin on Glycemic Control by Race-Ethnicity.
- Race and association of angiotensin converting enzyme/angiotensin receptor blocker exposure with outcome in heart failure.
- Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel Treated Patients Following Acute Myocardial Infarction.
- Epidemology and outcomes associated with anemia during long-term support with continuous-flow left ventricular assist devices.
- Safety of Anticoagulation Reversal in Patients Supported with Continuous-flow Left-ventricular Assist Devices.
- Gap between clinical guidelines and practice: The case of aldosterone-antagonists in patients with myocardial infarction.
- Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups.
- High Rates of False-Positive Hepatitis C Antibody Tests Can Occur After Left Ventricular Assist Device Implantation.
- Insulin Resistance Is Associated With Significant Clinical Atherosclerosis in Nondiabetic Patients With Acute Myocardial Infarction.
- Acute Intravenous Infusion of an Adenosine Regulating Agent Improves Left Ventricular Function in Dogs with Advanced Heart Failure.
- Association of Genetic Variation with Gene Expression and Protein Abundance within the Natriuretic Peptide Pathway.
- Impact of continuous-flow left ventricular assist device support on right ventricular function.
- Ventricular assist devices: is destination therapy a viable alternative in the non-transplant candidate?
- Comparison of Beta-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction.
- Patients with low compared with high body mass index gain more weight after implantation of a continuous-flow left ventricular assist device.
- Effect of Ezetimibe on Major Atherosclerotic Disease Events and All-Cause Mortality.
- Management of aortic valve insufficiency in patients supported by long-term continuous flow left ventricular assist devices.
- Comparison of renal predictors for in-hospital and postdischarge mortality after hospitalized heart failure.
- Gastrointestinal bleeding with the HeartMate II left ventricular assist device.
- Non-cardiac surgery in patients on long-term left ventricular assist device support.
- Association of Beta Blocker Exposure with Outcomes in Heart Failure Differs Between African American and White Patients.
- Pharmacogenetics in Chronic Heart Failure: New Developments and Current Challenges.
- Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence.
- Factors influencing patient willingness to participate in genetic research after a myocardial infarction.
- ACCF/AHA/HFSA 2011 Survey Results: Current Staffing Profile of Heart Failure Programs, Including Programs That Perform Heart Transplant and Mechanical Circulatory Supp...
- Genome-wide approach to identify novel candidate genes for beta blocker response in heart failure using an experimental model.
- Relation of worsened renal function during hospitalization for heart failure to long-term outcomes and rehospitalization.
- Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma.
- Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients.
- A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma.
- Genetic variation in the natriuretic peptide system and heart failure.
- Effect of "energy drink" consumption on hemodynamic and electrocardiographic parameters in healthy young adults.
- Race-ethnic differences in factors associated with inhaled steroid adherence among adults with asthma.
- Myoglobin and troponin I elevation predict 5-year mortality in patients with undifferentiated chest pain in the emergency department.
- Relationship between recent short-acting beta-agonist use and subsequent asthma exacerbations.
- Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker i...
- Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence.
- Pharmacogenetics: using DNA to optimize drug therapy.
- Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome.
- Genetic variation in the B-type natiuretic peptide pathway affects BNP levels.
- Beta2-adrenergic receptor genotype predicts survival: implications and future directions.
- Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.
- Caution with beta1-adrenergic receptor genotyping.
- Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans.
- Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
- Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure.
- Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure.
- Comparing methods for identifying patients with heart failure using electronic data sources.
- Progress toward genetic tailoring of heart failure therapy.
- Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes.
Schools
University Of Michigan Medical School
Washington UniversityBarnes Jewish Hospital
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Fellow (FAHA)
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACC)
Education
-
University of Michigan School of Public Health -
Washington University -
Washington University - Barnes-Jewish Hospital -
University of Michigan Medical School
Hospital
-
Henry Ford Hospital
Drug Facts
| NPI NUMBER | 1184792632 | |
| NPPES Provider LastName | LANFEAR | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 48202 | |
| NPPES Provider State | MI | |
| Specialty Description | Cardiology | |
| Total Claim Count | 662.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184792632 |
| Last Name Of The Provider | LANFEAR |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Maithili H. Shenoy, MD |
|
|
Dr. Anupama R. Kottam, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pawan K. Hari, MD |
|
Dr. Mouaz H. Al-Mallah, MD |
|
Dr. Kan D. Fang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Neelima Nadella, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joya A. Ganguly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zain Azzo, MD |
|
|
Dr. Zeia R. Casab, MD |
|
|
Dr. Chike U. Obi, MD |
|
|
Bhavana Siddegowda Bangalore, MB BS
This Doctor is OpenDoctor Recommended.
|